11 hours Ago By ABMN Staff
Glaukos ( NYSE:GKOS – Get Free Report ) was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating in a note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $120.00 price target on the medical instruments supplier’s stock.
Morgan Stanley’s price objective would suggest a potential downside of 11.76% from the stock’s previous close. Other equities research analysts have also recently issued reports about the stock.
Piper Sandler set a $140.00 price objective on shares of Glaukos in a research report on Thursday, October 17th. Stifel Nicolaus boosted their price target on Glaukos from $130.
00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Truist Financial increased their price objective on Glaukos from $145.
00 to $152.00 and gave the stock a “buy” rating in a report on Monday, October 14th. BTIG Research boosted their target price on Glaukos from $140.
00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, StockNews.
com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.
com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $136.18. Read Our Latest Stock Analysis on GKOS Glaukos Price Performance Glaukos ( NYSE:GKOS – Get Free Report ) last released its quarterly earnings results on Monday, November 4th.
The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.
20. The company had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.
50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.
43%. Glaukos’s revenue was up 23.9% compared to the same quarter last year.
During the same quarter last year, the firm posted ($0.50) earnings per share. On average, research analysts expect that Glaukos will post -1.
91 EPS for the current year. Insider Transactions at Glaukos In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th.
The shares were sold at an average price of $138.97, for a total value of $316,156.75.
Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $14,198,425.93. This represents a 2.
18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, Director Gilbert H.
Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.
00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12.
This represents a 8.49 % decrease in their position. The disclosure for this sale can be found here .
6.40% of the stock is currently owned by corporate insiders. Hedge Funds Weigh In On Glaukos A number of large investors have recently made changes to their positions in the company.
Values First Advisors Inc. acquired a new position in Glaukos in the 3rd quarter valued at $25,000. Harvest Fund Management Co.
Ltd grew its stake in shares of Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co.
Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Glaukos by 68.8% in the second quarter.
GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after acquiring an additional 486 shares in the last quarter. KBC Group NV increased its position in Glaukos by 16.2% during the third quarter.
KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 201 shares during the period. Finally, EWA LLC bought a new stake in Glaukos in the 3rd quarter valued at about $209,000. Institutional investors own 99.
04% of the company’s stock. Glaukos Company Profile ( Get Free Report ) Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Read More Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter ..
